Condition (MeSH)
HIV Enteropathy
ClinicalTrials.gov lists 3 trials for HIV Enteropathy or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 3 trials are tagged with HIV Enteropathy itself; the rest are tagged with a narrower condition beneath it.
When did HIV Enteropathy trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2013 | 1 |
| 2011 | 1 |
| 1998 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are HIV Enteropathy trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 1 |
How many HIV Enteropathy trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most HIV Enteropathy trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bausch Health Americas, Inc. | 1 |
| Entera Health, Inc | 1 |
Which serious adverse events do HIV Enteropathy trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| CELLULITIS | 4 | 1 |
| PAIN IN EXTREMITY | 2 | 1 |
| SUICIDE ATTEMPT | 2 | 1 |
| ABSCESS LIMB | 1 | 1 |
| ANAL CANCER | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover HIV Enteropathy? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. | AIDS (London, England) | 2013 | Yes |
| Enteropathies in the developing world: neglected effects on global health. | The American journal of tropical medicine and hygiene | 2012 | Yes |
| Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics. | International reviews of immunology | 2010 | Yes |
| Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. | Gastroenterology | 2009 | Yes |
| HIV infection and the gastrointestinal immune system. | Mucosal immunology | 2008 | Yes |
Showing 5 of 8 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.